Mindpeak announces CE-mark for new product: Breast HER2 RoI

„I am very pleased that with our new software we can make a contribution to breast cancer therapy. It is especially interesting as the Trastuzumab-Deruxtecan (Enhertu) therapy – has recently become available, where the distinction between "0" (negative) and "1+" (weakly positive = HER2low) is now important – something that pathologists were not used to distinguishing until now. Here, an AI that delivers reproducible results can support pathologists particularly well“, says Mindpeak’s CEO and founder Felix Faber. 

Founded by Faber and Dr Tobias Lang, the company has been developing AI-software for pathologists since 2018. In doing so, Mindpeak has developed the first AI solution for digital pathology to make it into clinical routine in both Europe and the US. In partnership with international laboratories and leading pathology system providers, Mindpeak continues to expand its product range and develop it into an indispensable part of the digitized pathology workflow. This has made Mindpeak the most integrated company in this field globally.